Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model

To assess the preclinical utility and functional mechanism of intraperitoneal anti-CX3CL1 mAb therapy in the skin and lung fibrosis, sclerodermatous chronic graft-versus-host disease (Scl-cGVHD) model mice were analyzed by RNA-sequencing assays. Overall design: Gene expression profiling analysis of RNA-seq data for skin, harvested from 3 syngenic mice dosed with control IgG, 5 syngenic mice dosed with anti-CX3CL1 mAb, 3 GVHD mice dosed with control IgG, 3 GVHD mice dosed with anti-CX3CL1 mAb (0.5 mg/head), and 5 GVHD mice dosed with anti-CX3CL1 mAb (1 mg/head).